Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,083 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,116
- Phase 1823
- Phase 1/Phase 2481
- Phase 3349
- Phase 4127
- Phase 2/Phase 379
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia122
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema50
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center64
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California406
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida111
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,083 total
- NCT05360160RecruitingPhase 1/Phase 2
Oral menin inhibitor plus AML medicines for new or relapsed AML
This trial tests an all-pill (oral) combination treatment—menin inhibitor SNDX-5613 plus decitabine/cedazuridine (ASTX727) and venetoclax—for acute myeloid leukemia (AML). It’s designed for people who are newly diagnosed and can’t get the strongest chemotherapy, or for certain other AML groups who may still benefit.
Houston, TexasAges 12 years+ - NCT05361694Recruiting
Study aims to distinguish stable vs worsening early myeloma
This study looks at two different “precursor” conditions that can happen before multiple myeloma: MGUS and smoldering myeloma (SMM). Researchers want to better tell which cases are more likely to progress, using blood/urine tests and sometimes bone marrow tissue.
Miami, FloridaAges 18 years+ - NCT05361980Recruiting
Study of safety and results of a pediatric bone implant
This study looks at whether a specific pediatric bone implant is safe and works well for children who need it. By joining, you help researchers track outcomes over time and understand possible implant-related side effects.
Vancouver, British ColumbiaAges birth–25 years - NCT05363111RecruitingPhase 1
Testing a targeted radioactive drug for relapsed myeloma
This Phase 1 study tests a targeted radioactive medicine made from daratumumab plus a radioactive payload, aiming to treat multiple myeloma that has come back or doesn’t respond to treatment. It’s designed mainly to check safety and how the treatment works in people who have had several prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT05365035RecruitingPhase 2
Phase 2 trial for high-risk blood cancers with timed chemo
This study tests a mix of medicines (cladribine, low-dose cytarabine, and venetoclax) alternated with azacitidine and venetoclax to treat higher-risk CMML or MDS after prior treatment or when standard treatment may not work well. It may help by improving blood counts and controlling the disease.
Houston, TexasAges 18 years+ - NCT05366569Recruiting
CAR T-cell therapy for certain blood cancers after relapse
This trial studies a type of immune therapy (CAR T-cells) for people whose leukemia or lymphoma has come back or did not respond after at least two treatment attempts. It aims to improve outcomes in carefully selected patients who can safely receive the treatment.
BresciaAges 18–70 - NCT05366699Recruiting
Procedure to help prevent arm swelling after breast surgery
This trial studies a new procedure meant to lower the chance of getting lymphedema (arm swelling) after breast cancer surgery that removes lymph nodes in the armpit. It may help patients reduce the risk of long-term arm swelling, especially after lymph node dissection.
San Francisco, CaliforniaAges 18–75 - NCT05366881Recruiting
Blood test study to spot early cancer signal and cancer leftovers
This observational study checks whether a blood test (a “cfDNA” test) can detect early signs of cancer or small amounts of cancer left after treatment. It may help doctors use a simple blood sample to improve cancer detection and follow-up.
Duarte, CaliforniaAges 40 years+ - NCT05367700RecruitingPhase 1
Test drug HS-10382 for chronic myeloid leukemia after prior treatment
This early-phase study tests HS-10382 in adults with chronic myeloid leukemia (CML) whose leukemia is resistant to or not tolerated of standard pills. It aims to see if the drug can control CML when earlier treatment hasn’t worked for you.
Wuhan, HubeiAges 18–74 - NCT05370430RecruitingPhase 1
CAR T therapy targeting BAFF-R for certain NHL
This Phase 1 study tests a new type of immune-cell therapy (CAR T cells) that targets BAFF-R to treat certain relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It aims to see if the treatment is safe and can shrink lymphoma in people who have tried prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT05371132RecruitingPhase 1
PET scan study to track immune response after SBRT
This early (Phase 1) study uses a special PET scan to measure how your immune system responds after stereotactic body radiation therapy (SBRT). The goal is to see whether the scan result can serve as a marker of immune response, which may help future treatment planning.
Duarte, CaliforniaAges 18 years+ - NCT05372354RecruitingPhase 1/Phase 2
Testing a new multiple myeloma drug with other treatments
This early-phase study tests how safe a new drug (CC-92480) is and how much it stays in the body, when given with other standard or study treatments. It’s for people whose multiple myeloma has come back or did not respond after prior therapy, with the goal of improving disease control.
Birmingham, AlabamaAges 18 years+ - NCT05373771Recruiting
Care plan for sickle cell pain crises in the ER
This trial studies an approach to improve care during emergency room visits for uncomplicated sickle cell pain crises. It may help by guiding how pain is treated in the ER and tracking outcomes for people with sickle cell disease.
Milwaukee, WisconsinAges Up to 18 years - NCT05375617Recruiting
Study for newly diagnosed childhood cancers in Europe
This study follows children and teens with newly diagnosed certain leukemia (ALL) and certain favorable brain tumors to learn best care and outcomes. It may help your team compare standard treatments and monitor health over time.
New York, New YorkAges 3–21 - NCT05375643Recruiting
Get help enrolling in a genomics-based cancer trial
This study helps support people who are from groups less represented in cancer genetics research to get enrolled in genomics-based cancer trials. If you’re starting a new patient visit for an advanced stomach, blood, or lung cancer, this may guide you through options that use your genetic information.
Boston, MassachusettsAges 18 years+ - NCT05376111RecruitingPhase 2
Venetoclax plus azacitidine for newly diagnosed T-ALL
This Phase 2 study tests whether venetoclax combined with azacitidine can treat newly diagnosed T-ALL, a type of leukemia. It may help reduce cancer activity and improve outcomes if you meet the safety and treatment timing requirements.
Suzhou, JiangsuAges 15 years+ - NCT05376046Recruiting
Study blood features and clot risk in sickle cell disease
This study looks at differences in red blood cells and how likely they are to form clots in people with sickle cell disease. The goal is to better understand clot risk and what blood markers may predict it.
RouenAges 18 years+ - NCT05377307Recruiting
Long-term follow-up for gene-edited immune cell therapy
This study checks how people are doing years after receiving a specific company’s gene-edited immune cell treatment. It helps researchers learn about long-term safety and health outcomes.
Kaohsiung, TaiwanAges Any age - NCT05378139Recruiting
At-home and hospital wireless monitoring for worsening health
This trial tests a system that continuously checks vital signs (like heart rate and breathing) using wireless sensors and sends automatic alerts if you seem to be getting worse. It may help clinicians spot problems sooner whether you’re being monitored at home or around a major surgery hospital stay.
Copenhagen, CopenhagenAges 18 years+ - NCT05378555RecruitingPhase 3
Oral ketamine for sickle cell pain crises
This trial tests whether taking ketamine by mouth can help treat “vaso-occlusive” pain episodes that may require hospital admission. If it works, it could offer an easier way to manage severe pain during sickle cell crises.
Boston, MassachusettsAges 12–24 - NCT05379738Recruiting
Exercise program to aid recovery after donor stem cell transplant
This trial tests whether an adapted physical activity (tailored exercise) can help people recover after a donor stem cell transplant for blood cancers. If you’re able to participate, the program may support strength, well-being, and recovery during the transplant process.
NiceAges 18 years+ - NCT05383911Recruiting
Sickle cell care plan choices for teens and young adults
This trial tests a way to help teens and young adults with sickle cell disease (SCD) and their caregivers actively take part in treatment decisions. It focuses on improving shared decision-making through interviews and a partner-centered approach.
Wilmington, DelawareAges 15 years+ - NCT05384288Recruiting
How kids with blood cancers respond to the flu vaccine
This study looks at how children with blood cancers respond to the seasonal flu shot. It may help doctors understand what protection the vaccine provides for pediatric oncology patients.
Memphis, TennesseeAges Up to 18 years - NCT05384691RecruitingPhase 2
Luspatercept for anemia in lower-risk MDS not needing transfusions
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
BerlinAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,083 recruiting hematology studies from the U.S. registry right now, out of 7,730 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.